Genovis AB (publ.) Past Earnings Performance
Past criteria checks 6/6
Genovis AB (publ.) has been growing earnings at an average annual rate of 54.5%, while the Life Sciences industry saw earnings growing at 30.7% annually. Revenues have been growing at an average rate of 28.2% per year. Genovis AB (publ.)'s return on equity is 32.2%, and it has net margins of 38.9%.
Key information
54.5%
Earnings growth rate
54.2%
EPS growth rate
| Life Sciences Industry Growth | 31.8% |
| Revenue growth rate | 28.2% |
| Return on equity | 32.2% |
| Net Margin | 38.9% |
| Next Earnings Update | 24 Apr 2024 |
Recent past performance updates
Recent updates
Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?
Mar 18
What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash
Feb 28We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings
Feb 22These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts
Feb 20Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be
Feb 04Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors
Oct 06Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?
Jun 22What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?
May 13Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?
Dec 22Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?
Nov 14If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity
Jul 08Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?
Jun 01Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%
May 10One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically
Feb 10Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?
Aug 09What Is Genovis AB (publ.)'s (STO:GENO) Share Price Doing?
Mar 27How Does Genovis AB (publ.)'s (STO:GENO) CEO Pay Compare With Company Performance?
Dec 30Is Now An Opportune Moment To Examine Genovis AB (publ.) (STO:GENO)?
Nov 23
Revenue & Expenses BreakdownBeta
How Genovis AB (publ.) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 158 | 62 | 79 | 0 |
| 30 Sep 23 | 158 | 54 | 78 | 0 |
| 30 Jun 23 | 151 | 57 | 76 | 0 |
| 31 Mar 23 | 142 | 42 | 73 | 0 |
| 31 Dec 22 | 104 | 11 | 68 | 0 |
| 30 Sep 22 | 119 | 41 | 64 | 0 |
| 30 Jun 22 | 112 | 36 | 60 | 0 |
| 31 Mar 22 | 111 | 36 | 57 | 0 |
| 31 Dec 21 | 94 | 25 | 53 | 0 |
| 30 Sep 21 | 71 | 11 | 52 | 0 |
| 30 Jun 21 | 69 | 12 | 51 | 0 |
| 31 Mar 21 | 65 | 9 | 50 | 0 |
| 31 Dec 20 | 61 | 6 | 47 | 0 |
| 30 Sep 20 | 54 | -3 | 46 | 0 |
| 30 Jun 20 | 64 | 3 | 43 | 0 |
| 31 Mar 20 | 60 | 6 | 41 | 0 |
| 31 Dec 19 | 61 | 10 | 39 | 0 |
| 30 Sep 19 | 58 | 12 | 36 | 0 |
| 30 Jun 19 | 43 | 5 | 33 | 0 |
| 31 Mar 19 | 40 | 1 | 32 | 0 |
| 31 Dec 18 | 35 | -2 | 30 | 0 |
| 30 Sep 18 | 31 | -4 | 29 | 0 |
| 30 Jun 18 | 27 | -6 | 28 | 0 |
| 31 Mar 18 | 24 | -7 | 28 | 0 |
| 31 Dec 17 | 23 | -8 | 28 | 0 |
| 30 Sep 17 | 21 | -9 | 28 | 0 |
| 30 Jun 17 | 21 | -9 | 27 | 0 |
| 31 Mar 17 | 20 | -14 | 31 | 0 |
| 31 Dec 16 | 19 | -15 | 37 | 0 |
| 30 Sep 16 | 17 | -16 | 39 | 0 |
| 30 Jun 16 | 16 | -21 | 42 | 0 |
| 31 Mar 16 | 14 | -18 | 40 | 0 |
| 31 Dec 15 | 14 | -20 | 35 | 0 |
| 30 Sep 15 | 13 | -25 | 41 | 0 |
| 30 Jun 15 | 11 | -24 | 36 | 0 |
| 31 Mar 15 | 10 | -23 | 30 | 0 |
| 31 Dec 14 | 10 | -22 | 26 | 0 |
| 30 Sep 14 | 8 | -20 | 24 | 0 |
| 30 Jun 14 | 10 | -17 | 24 | 0 |
| 31 Mar 14 | 11 | -16 | 23 | 0 |
| 31 Dec 13 | 10 | -16 | 23 | 0 |
| 30 Sep 13 | 10 | -19 | 21 | 0 |
| 30 Jun 13 | 9 | -19 | 21 | 0 |
Quality Earnings: GENO has high quality earnings.
Growing Profit Margin: GENO's current net profit margins (38.9%) are higher than last year (10.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GENO has become profitable over the past 5 years, growing earnings by 54.5% per year.
Accelerating Growth: GENO's earnings growth over the past year (449.6%) exceeds its 5-year average (54.5% per year).
Earnings vs Industry: GENO earnings growth over the past year (449.6%) exceeded the Life Sciences industry 46.4%.
Return on Equity
High ROE: GENO's Return on Equity (32.2%) is considered high.